CP-751,871, an IGF-1R inhibitor, investigated with chemotherapy for advanced NSCLC survival

Non-small cell lung cancer (NSCLC) remains a leading cause of cancer mortality, particularly in advanced stages. Standard chemotherapy regimens often yield limited long-term survival benefits, necessitating novel therapeutic strategies. The insulin-like growth factor 1 receptor (IGF-1R) pathway is implicated in cancer cell proliferation, survival, and metastasis, making it a promising target for intervention. Inhibiting IGF-1R could potentially enhance the efficacy of conventional chemotherapy by disrupting key growth and survival signals in cancer cells. This study explores this synergistic approach.

This Phase 1b/2 randomized, non-comparative, open-label study evaluated CP-751,871 combined with paclitaxel and carboplatin as first-line treatment for advanced NSCLC (squamous, large cell, adenosquamous histology). Patients had locally advanced (Stage IIIB with pleural effusion) or metastatic (Stage IV or recurrent) disease. The intervention arm received CP-751,871 20 mg/kg IV over 2.5 hours (up to 17 cycles) alongside carboplatin (AUC 6, IV, up to 6 cycles) and paclitaxel. The primary endpoint was to determine if adding CP-751,871 prolonged survival.

The provided abstract and study description do not contain specific efficacy or safety results from this completed Phase 2 trial. The study aimed to determine if the addition of CP-751,871 prolonged survival in the target patient population, but the outcomes are not detailed here.